Johnson Bixby & Associates LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,711 shares of the company’s stock after purchasing an additional 68 shares during the quarter. Johnson Bixby & Associates LLC’s holdings in Johnson & Johnson were worth $1,111,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. raised its position in Johnson & Johnson by 1.4% in the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after acquiring an additional 2,688,798 shares in the last quarter. Moneta Group Investment Advisors LLC raised its position in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC increased its stake in Johnson & Johnson by 1.6% in the 1st quarter. Geode Capital Management LLC now owns 48,707,500 shares of the company’s stock worth $7,532,525,000 after purchasing an additional 748,917 shares in the last quarter. Morgan Stanley increased its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Finally, Norges Bank purchased a new position in Johnson & Johnson in the 4th quarter worth about $4,609,399,000. 68.40% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Down 0.1 %
JNJ opened at $158.35 on Wednesday. The business has a 50 day moving average price of $163.91 and a 200 day moving average price of $162.50. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $411.55 billion, a P/E ratio of 32.05, a price-to-earnings-growth ratio of 3.19 and a beta of 0.55.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Royal Bank of Canada started coverage on Johnson & Johnson in a research note on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Raymond James dropped their price target on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 5th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 31st. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.06.
View Our Latest Report on Johnson & Johnson
Insider Transactions at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Upcoming IPO Stock Lockup Period, Explained
- 5 Reasons Gilead Sciences is a Better Buy Than You Think
- Investing in Agriculture 101: How to Invest in Agriculture
- Jobs Are Going To The Construction Industry, Momentum Play Time
- Investing in the High PE Growth Stocks
- PepsiCo Q3 Strength Results In A Trend Following Buy Signal
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
